slides · global inventory
List
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,539
Current window 92,851-92,880
Pages 3,685
Rows per page 30
Component
92,851-92,880 of 110,539
03
Nuvalent | Investor Presentation Deck | 41 slidesNuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
04
The slide uses a 'ribbon' layout to highlight four key pillars of the company's methodology.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
06
The slide uses a timeline framework to connect high-level goals with specific 2024 milestones.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
07
The slide uses a split layout with a left panel for advisors/board and a right panel for the leadership team and a footer metric.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
08
The slide uses a Gantt-style visualization to represent drug development stages.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
11
The chart visualizes the dominance of Alectinib and Crizotinib in the current market landscape.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations Beat · Market SizingLoop · Cost Of Inaction1 hit
21
The chart is a classic swimmer plot used in oncology clinical trials to visualize time-to-event data.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
23
Data cut-off: 8 Aug 2023. N=93 patients.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
25
The slide outlines a multi-cohort study design with specific patient populations and trial objectives.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
32
Includes a summary table of best responses and a waterfall plot showing percentage change in target lesions by dose cohort.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
34
Data as of 13 Sep 2022. N=35 patients.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
35
The chart shows pharmacokinetic curves for four different dose levels against four target efficacy thresholds.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
36
The slide uses a comparative framework to highlight unmet needs in 2L+ and the potential for market leadership in 1L.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
37
The slide outlines a multi-cohort study design for NVL-520, distinguishing between registrational cohorts and an exploratory cohort.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
40
The slide highlights the 'OnTarget 2026' initiative, which serves as a strategic milestone for product approval.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
06
The slide uses a timeline to connect corporate strategy to specific clinical trial milestones.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Solution1 hit
07
The slide features a split layout with a left-hand column for advisors/board and a right-hand grid for the leadership team, plus a footer highlighting 12 prior FDA approvals.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Solution1 hit
11
The chart visualizes the dominance of Alectinib and Crizotinib in the current market landscape.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Market SizingLoop · Cost Of Inaction1 hit
15
The slide presents two distinct scientific data sets: an IC50 dot plot for in vitro activity and a bar chart for in vivo tumor regression.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
22
Swimmer plot visualization of clinical trial patient outcomes.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
24
Data cut-off: 8 Aug 2023. N=93 treated patients.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
33
Includes a summary table of ORR and best response, and a waterfall plot showing individual patient tumor regression.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
35
Data as of 13 Sep 2022. N=35 patients.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
36
The chart shows pharmacokinetic data (NVL-520 concentration over time) compared against target efficacy thresholds for different ROS1 variants.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
38
The slide outlines a multi-cohort clinical trial design with specific patient segments based on prior treatment history.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
41
The slide uses a timeline framework to connect current clinical progress to a 2026 goal of product approval.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
07
Includes a biological pathway diagram and a dose-response curve showing target validation.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
08
The slide presents experimental evidence (Western blot) supporting the mechanism of action for NXP800 in ARID1a-deficient cancer cells.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
10
Includes a patient-derived xenograft (PDX) study methodology diagram and a line chart showing tumor volume over time.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
11
The slide presents three separate line charts showing tumor growth inhibition over time for different cell lines (RL95-2, KLE, SNG-M).Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit